The ThinPrep Pap Test is the only liquid-based pap test FDA-approved for HPV, Gonorrhea, and Chlamydia testing straight from the vial. Moreover, the ThinPrep Pap Test is the only pap test with FDA-approved labeling supported by multiple peer-reviewed publications showing increased glandular disease detection.1-6
For women over 30 years old, who are most at risk of cervical cancer, getting both tests provides the best assurance of finding cervical disease before it becomes cancer. Studies show that, on average, the combination of the digene HPV Test and the Pap identifies 95-100 percent of advanced cervical disease (CIN 2, CIN 3, or cancer). It is important to remember, however, that the presence of HPV does not mean you have cervical disease. An additional exam is needed to determine whether disease exists.
National Cancer Institute studies have shown that women with HPV types 16 and 18 have about a 20% risk of progressing to CIN3 over 10 years despite negative Pap tests, and colposcopy may be useful for these women. However, most HPV 16/18 infections regress, especially in women under age 30, who also have almost a 20% rate of high risk HPV infection. The 2006 Consensus Guidelines included a statement that in cytology negative women ages 30 years and older who are high-risk HPV DNA positive it would be reasonable to obtain genotyping assays for HPV 16 and 18. Women who were positive should be referred for immediate colposcopy, while those who are HPV 16/18 negative but positive for other high-risk types should be followed with repeat cytology and high-risk HPV testing in 12 months. Because a FDA-approved HPV genotyping assay was not available in 2006, this recommendation was made contingent on approval of such an assay. The first HPV genotyping assay was approved in March 2009 and based on this approval ASCCP released the Management Algorithm for Using HPV Genotyping to Manage HPV High-risk Positive / Cytology Negative Women 30 Years and Older. Note that it is also reasonable to manage women who are Pap negative but high-risk HPV positive by repeating both tests in 12 months. Genotyping assays are not suitable for women who are younger than 30 years old. Genotyping is inappropriate for women with abnormal Pap results, as results do not alter management.
The oncoFISH cervical test is an automated qualitative fluorescence in situ hybridization (FISH) test for determining the acquisition of specific chromosomal aneuploidies within the 3q26 region in cytological specimens revealing LSIL. oncoFISH cervical provides information to assist the physician in the clinical management of LSIL prior to colposcopy. Approximately 10% of patients diagnosed with LSIL will progress to HSIL, 60% will regress to normal and 30% will remain LSIL (Nasiell K, et al. 1986, Ostor AG, et al. 1993, Melnikow J, et al. 1998, Holowaty P, et al. 1999, Wright TC, et al. 2007.) Historically, it has not been possible to identify which patients will progress or not. The oncoFISH cervical test provides a predictive tool to aid the clinician in managing an LSIL diagnosis.
The APTIMA COMBO 2 Assay is a target amplification nucleic acid probe test that utilizes target capture for the in vitro qualitative detection and differentiation of ribosomal RNA (rRNA) from Chlamydia trachomatis (CT) and/or Neisseria gonorrhoeae (GC) to aid in the diagnosis of chlamydial and/or gonococcal urogenital disease using the TIGRIS DTS Automated Analyzer or semi-automated instrumentation as specified. The assay may be used to test the following specimens from symptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; and female and male urine specimens. The assay may be used to test the following specimens from asymptomatic individuals: clinician-collected endocervical, vaginal and male urethral swab specimens; patient-collected vaginal swab specimens1; and female and male urine specimens. The assay is also intended for use with the testing of gynecological specimens, from both symptomatic and asymptomatic patients, collected in the PreservCyt Solution. Patient-collected vaginal swab specimens are an option for screening women when a pelvic exam is not otherwise indicated.
BX-1 day TAT
TAT 1-2 days on routine, special stains may take longer
The Continuity of Care Record (CCR) is a core data set of the most relevant administrative, demographic, and clinical information facts about a patient's healthcare, covering one or more healthcare encounters. Following the patients care cycle from annual screening to surgical procedures to follow up care and ensures best patient outcomes, managed utilization of clinical diagnostics and control of healthcare dollars spent.
In the world of electronic medical recordst provides a means for one healthcare practitioner, system, or setting to aggregate all of the pertinent data about a patient and forward it to another practitioner, system, or setting to support the continuity of care. The primary use case for the CCR is to provide a snapshot in time containing the pertinent clinical, demographic, and administrative data for a specific patient. Additionally, conditions of security, privacy , and a structured electronic format specification must be established in a way that allows only authenticated and authorized user access to the CCR document.
The Department of Laboratory Medicine and Pathology at Collaborative Laboratory Services provides a comprehensive spectrum of tests necessary for the diagnosis and treatment of all medical problems. Quality control procedures have been developed to ensure consistent testing and integrity of results. Consultations on all problems relating to laboratory medicine, clinical and anatomic pathology, hematopathology and dermatopathology consults are available by calling 860-714-4280.
Specialized services in dermatopathology are available through Collaborative Laboratory Services. Dr. Philip Shapiro accepts specimens for consultation and clinical correlation of inflammatory, degenerative, benign, and malignant skin diseases. Arrangements for special stains and immunofluorescence can be made in advance of surgical procedure to ensure proper collection and transport integrity of specimens. Descriptive and differential diagnosis are available. Reports by mail, fax or phone can be arranged.
Prenatal genetic testis are performed during pregnancy to screen for or diagnose a birth defect. The main goal of prenatal genetic testing is to provide families with information to make informed choices about pregnancy and reproduction, and to assist the woman's physician in providing the best care and management for her pregnancy. Collaborative Laboratory Services refers this testing to Mayo Medical Laboratories as it is our partner in healthcare and known for their clinical expertise.
Copyright © 2014 Collaborative Laboratory Services, LLC. All rights reserved. All information is intended for your general knowledge and is not a substitute for medical advice or treatment for specific medical conditions. You should seek prompt medical care for any specific health issues and consult your physician before starting a new fitness regimen.
Website Developed by: TCC Web Interactive a division of The Computer Company, Inc.
Powered by eManagerSite - CMS for Business.